Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why NeoGenomics (NEO) Stock Is Nosediving

April 29, 2025 at 15:49 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NEO Cover Image

What Happened?

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-year revenue guidance exceeded Wall Street's estimates. Overall, this quarter was mixed. The areas below expectations seemed to be driving the move.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.

What The Market Is Telling Us

NeoGenomics’s shares are extremely volatile and have had 31 moves greater than 5% over the last year. But moves this big are rare even for NeoGenomics and indicate this news significantly impacted the market’s perception of the business.

The biggest move we wrote about over the last year was 2 months ago when the stock dropped 21.5% on the news that the company reported weak fourth-quarter results, with revenue falling below Wall Street's expectations. Also, the result revealed minimal bottom-line improvement, as the business remained unprofitable. Further weighing on results, the company posted negative free cash flow for the quarter. On the other hand, guidance was more encouraging as full-year sales and EBITDA outlook were both ahead of consensus estimates. Overall, this was a challenging quarter.

NeoGenomics is down 60.8% since the beginning of the year, and at $6.47 per share, it is trading 65.3% below its 52-week high of $18.61 from January 2025. Investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at an investment worth $208.41.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article